Travere Therapeutics (NASDAQ: TVTX) insider transactions

In the twelve months to 10 November 2026, executives and directors of Travere Therapeutics reported 118 open-market sales of 2,127,271 shares ($110.4m) and 0 open-market purchases, by 11 people, according to the Form 4 filings they submitted to the SEC.

Latest transactions

The 20 most recent transactions in Travere Therapeutics shares reported on Form 4
Date	Insider	Role	Transaction	Shares	Price	Held after	Filing
15 October 2026	Dube Eric M	Chief Executive Officer	Option exercise, 10b5-1 plan	+43,735	$26.88	476,621	Form 4
15 October 2026	Dube Eric M	Chief Executive Officer	Option exercise, 10b5-1 plan	+200,000	$8.93	676,621	Form 4
15 October 2026	Dube Eric M	Chief Executive Officer	Open-market sale, 10b5-1 plan	−128,065	$52.97	548,556	Form 4
15 October 2026	Dube Eric M	Chief Executive Officer	Open-market sale, 10b5-1 plan	−37,270	$54.20	511,286	Form 4
15 October 2026	Dube Eric M	Chief Executive Officer	Open-market sale, 10b5-1 plan	−78,400	$55.02	432,886	Form 4
17 September 2026	Dube Eric M	Chief Executive Officer	Open-market sale, 10b5-1 plan	−6,802	$64.95	432,886	Form 4
17 September 2026	Dube Eric M	Chief Executive Officer	Option exercise, 10b5-1 plan	+108,493	$23.34	541,379	Form 4
17 September 2026	Dube Eric M	Chief Executive Officer	Open-market sale, 10b5-1 plan	−101,691	$64.59	439,688	Form 4
17 September 2026	Heerma Peter	EVP, Chief Commercial Officer	Option exercise, 10b5-1 plan	+8,282	$22.40	125,348	Form 4
17 September 2026	Heerma Peter	EVP, Chief Commercial Officer	Open-market sale, 10b5-1 plan	−8,282	$65.07	117,066	Form 4
16 September 2026	Rote William E.	Chief Research Officer	Open-market sale, 10b5-1 plan	−47,746	$63.61	98,197	Form 4
16 September 2026	Rote William E.	Chief Research Officer	Option exercise, 10b5-1 plan	+350	$17.96	98,547	Form 4
16 September 2026	Rote William E.	Chief Research Officer	Option exercise, 10b5-1 plan	+55,000	$15.46	153,547	Form 4
16 September 2026	Rote William E.	Chief Research Officer	Option exercise, 10b5-1 plan	+57,500	$26.88	211,047	Form 4
16 September 2026	Rote William E.	Chief Research Officer	Open-market sale, 10b5-1 plan	−65,104	$63.12	145,943	Form 4
16 September 2026	Dube Eric M	Chief Executive Officer	Option exercise, 10b5-1 plan	+195,841	$23.34	628,727	Form 4
16 September 2026	Dube Eric M	Chief Executive Officer	Open-market sale, 10b5-1 plan	−99,716	$63.26	529,011	Form 4
16 September 2026	Dube Eric M	Chief Executive Officer	Open-market sale, 10b5-1 plan	−96,125	$63.64	432,886	Form 4
16 September 2026	Heerma Peter	EVP, Chief Commercial Officer	Open-market sale, 10b5-1 plan	−93,604	$63.25	196,179	Form 4
16 September 2026	Heerma Peter	EVP, Chief Commercial Officer	Open-market sale, 10b5-1 plan	−79,113	$63.65	117,066	Form 4

Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.

How to read the table

Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.

Where each row comes from

From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Travere Therapeutics page; the method, in data sources.

Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.